– USA, MA – MC10, Inc. today announced that Dr. Paul Bleicher has joined the company’s Board of Directors.
“Paul Bleicher’s experience, ranging from his medical background to his substantial leadership expertise in the healthcare industry, positions him perfectly to join MC10’s Board of Directors,” commented Scott Pomerantz, Chief Executive Officer of MC10. “We welcome him to the team and are confident that his goals of improving patient care and furthering innovation will add tremendous value as MC10 continues to evolve.”
Dr. Bleicher is the Chief Executive Officer of OptumLabs™, an open, collaborative healthcare research and innovation center founded by a partnership between UnitedHealth Group’s Optum division and Mayo Clinic, and headquartered in Cambridge, Massachusetts. Together with over 20 diverse partners, OptumLabs strives to accelerate improvements in patient care and patient value through scientific discovery and innovation driven by insights from big data.
“I look forward to joining the MC10 Board and to contributing to the company’s forward thinking vision of providing optimized and individualized care to patients through digital healthcare solutions,” stated Dr. Bleicher.
Until the company’s acquisition by Optum in 2013, Dr. Bleicher was the Chief Medical Officer and a board member for Humedica, the foremost clinical intelligence provider of private cloud-based solutions for the healthcare industry. At the Boston-based company, Dr. Bleicher managed analytic operations, oversaw clinical strategy, and led product management and regulatory affairs teams. In 1997, Dr. Bleicher was a founder of Phase Forward, a company that pioneered the commercial electronic data capture (EDC) market and became a leading provider of integrated data management solutions for clinical trials and drug safety. He held several titles including CEO, Chief Strategy Officer, and Chairman and member of the Board of Directors from initial founding until Oracle acquired the company in 2010.
Dr. Bleicher earned his Bachelor of Science in Biology from Rensselaer Polytechnic Institute and his MD and PhD in Microbiology from the University of Rochester School of Medicine and Dentistry. He trained in internal medicine at the Beth Israel Hospital, dermatology at the Massachusetts General Hospital/Harvard Medical School program, and did a post-doctoral fellowship at the Dana-Farber Cancer Center. He began his career as an Assistant Professor of Dermatology at the Massachusetts General Hospital and Harvard Medical School.
Dr. Bleicher is a member of the National Academy of Medicine’s Leadership Consortium for Value and Science-Driven Healthcare (formerly the Institute of Medicine’s Roundtable on Value and Science-Driven Healthcare), and serves on the editorial board of Therapeutic Innovation and Regulatory Science. He has been the recipient of several awards including the Ernst and Young Entrepreneur of the Year Award in New England, the 2003 Rensselaer Alumni Association Fellows Award, the 2011 Alumni Key Award, and the 2015 William F. Glaser ’53 Rensselaer Entrepreneur of the Year Award. He has also been named one of PharmaVoice’s 100 Most Inspiring Leaders in Life Science, and been recognized as a Champion in Healthcare by the Boston Business Journal.
About MC10, Inc.
MC10 is a private company, backed by a strong syndicate of financial and strategic investors, that is improving human health through digital healthcare solutions. The company combines its proprietary ultra-thin, flexible body-worn sensors with advanced analytics to unlock health insights from physiological data. MC10 has received widespread recognition for its revolutionary technology and was recently named in Fast Company’s Most Innovative Companies in 2016 as a leader in healthcare. MC10 is headquartered in Lexington, MA.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
